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Background: Cell line models have proven to be effective tools to investigate a variety of ovarian cancer features.
Due to the limited number of cell lines, particularly of the serous subtype, the heterogeneity of the disease, and the
lack of cell lines that model disease progression, there is a need to further develop cell line resources available for
research. This study describes nine cell lines derived from three ovarian cancer cases that were established at initial
diagnosis and at subsequent relapse after chemotherapy.
Methods: The cell lines from three women diagnosed with high-grade serous ovarian cancer (1369, 2295 and
3133) were derived from solid tumor (TOV) and ascites (OV), at specific time points at diagnosis and relapse (R).
Primary treatment was a combination of paclitaxel/carboplatin (1369, 3133), or cisplatin/topotecan (2295). Second
line treatment included doxorubicin, gemcitabine and topotecan. In addition to molecular characterization (p53,
HER2), the cell lines were characterized based on cell growth characteristics including spheroid growth, migration
potential, and anchorage independence. The in vivo tumorigenicity potential of the cell lines was measured.
Response to paclitaxel and carboplatin was assessed using a clonogenic assay.
Results: All cell lines had either a nonsense or missense TP53 mutations. The ability to form compact spheroids or
aggregates was observed in six of nine cell lines. Limited ability for migration and anchorage independence was
observed. The OV3133(R) cell line, formed tumors at subcutaneous sites in SCID mice. Based on IC50 values and
dose response curves, there was clear evidence of acquired resistance to carboplatin for TOV2295(R) and OV2295
(R2) cell lines.
Conclusion: The study identified nine new high-grade serous ovarian cancer cell lines, derived before and after
chemotherapy that provides a unique resource for investigating the evolution of this common histopathological
subtype of ovarian cancer.
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Epithelial ovarian cancer (EOC) is the most lethal
gynecological malignancy. The most common histo-
pathogical subtype, serous, accounts for at least 50% of
EOC [1,2]. Ovarian cancer grade ranges from low (highly
differentiated) to high (poorly differentiated). Stage (I-
IV) is classified according to the degree of spread of the
disease with stage I confined to the ovaries, and stage IV
associated with distant metastases. A particular feature
of EOC is the formation of ascites, a peritoneal fluid
with a cellular fraction of ovarian cancer cells, lympho-
cytes, and mesothelial cells [3,4]. While serous EOC was
initially described as derived from the ovarian surface
epithelia, there is a growing debate that the cancer may
originate from the fallopian epithelia [5-7]. EOC is
largely asymptomatic, is most frequently diagnosed at
stages III-IV where the five year survival rate is typically
only 30% [6]. Treatment options for EOC involve cytore-
ductive surgery and a combination of cisplatin/taxol as a
first line of chemotherapy [8]. For early stage disease,
progression free survival is determined as the end point,
whereas for recurrent cancer, symptom control and
quality of life are the primary treatment goal [9].
Chemotherapy response is often determined by a com-
bination of CA-125 levels, and imaging methods such as
MRI and CT scans [10,11].
Cell line models have proven to be effective tools in
ovarian cancer research and have been utilized to inves-
tigate the molecular and cellular features of ovarian can-
cer [5,12]. We have demonstrated that EOC cell lines
derived from spontaneous growth of tumor cells in cul-
ture retain many of the growth and molecular genetic
characteristics of the original tumor [13]. Using ovarian
cancer cell lines we have derived, we have investigated
gene expression [14-18], chromosome content [19] and
gene mutations [13,19]. They have also been a resource
to study growth properties such as invasion and prolif-
eration [13,20,21]. Despite the usefulness of the available
cell lines, the serous subtype is under represented and
there is a need for additional ovarian cancer cell lines to
address the heterogeneity of the disease. Furthermore,
few cell lines have been derived from treatment naïve
patients, and often the resource is derived from patients
that have undergone rounds of chemotherapy. In order
to fully appreciate the disease and its evolution, it would
be beneficial to derive cell lines from the same patient
both at presentation and during the course of the dis-
ease. To date, only one report has described such a re-
source, exclusively derived from high grade serous
ovarian ascites, where cisplatin alone was the first line
therapy [22].
This study evaluated ovarian cancer cell lines derived
from the same patient at diagnosis and at relapse follow-
ing exposure to chemotherapy. The cell lines weredeveloped from solid tumors and ascites. Nine cell lines
were developed from specimens obtained from three
patients diagnosed with high-grade serous ovarian can-
cer. The cell lines were characterized biologically by
growth rates, morphology, ability of forming three-
dimensional spheroids, migration and invasion potential,
and their in vivo capacity to form tumors in SCID mice.
Mutational status for genes important in serous EOC
such as TP53, BRCA1 and BRCA2 were investigated. In-
formation on disease progression and treatment regi-
mens are included. In addition, we have characterized
the chemosensitivity of the cell lines to paclitaxel and
carboplatin by clonogenic assays. These cell lines pro-
vide novel and comprehensive models for the study of
EOC progression, ascites formation and resistance to
chemotherapy.Methods
Patient and sample data
Tumor and ascites samples were collected with informed
consent from the Centre hospitalier de l’Université de
Montréal (CHUM), Hôpital Notre-Dame, in the Depart-
ment of Gynecologic Oncology. The study was approved
by the Comité dé’thique de la recherché du CHUM, the
institutional ethics committee. Stage was determined at
time of surgery by a gynecologic oncologist. Histopath-
ology and tumor grade were determined by pathology
using criteria consistent with the International Federation
of Gynecology and Obstetrics (FIGO) classification [23]).Cell line establishment and culture conditions
In total, nine cell lines were derived from three patients.
The patients were coded with the unique identifiers
1369, 2295 and 3133. All cell lines were maintained in
hypoxic condition of 5% O2, and 5% CO2 and grown in
complete OSE medium, which includes OSE medium
(Wisent, Montreal, QC), 10% FBS, 0.5 μg/mL amphoter-
icin B (Wisent, Montreal, QC) and 50 μg/mL gentamicin
(Gibco, Grand Island, NY). The solid ovarian tumor
(TOV) derived cell lines (TOV1369, TOV2295(R),
TOV3133G and TOV3133D) were established using the
scrape method as previously described [19,24,25]. Briefly,
tumor tissue was scraped into a 100 mm plate with
complete OSE medium and maintained for 40 days with
the medium replaced weekly. Cells were passaged at
near confluence, and were considered immortal when
passaged over 50 times. The OV cell lines (OV1369(R2),
OV2295, OV2295(R2), OV3133(R), OV3133(R2)) were
established from the cellular fraction of ascites collected
by centrifugation [25]. The cell lines derived from ascites
cells were maintained as above for the TOV derived cell
lines. Each cell line has reached greater than 100 pas-
sages, with the exception of TOV3133D (84 passages).
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lines at passages between 60 and 80.
Cell Growth rates
Growth rates were assessed as previously described
[13,19]. Briefly, cells were seeded on day 0 in 6-well
plates (1 x 105 cells per well for the 1369 and 2295 cell
lines and 2 x 105 cells per well for 3133 cell lines). The
OSE complete media was replaced every 3 days for the
duration of the experiment. Every second day from day
1 to 13, cells were trypsinized, resuspended in media
and counted using the CASY analyzer system. Saturation
density was defined as the mean maximum number of
cells counted at the time of confluence. Each experiment
was performed in duplicate, and repeated three times.
Doubling times were determined using a publically avail-
able algorithm [26].
Antibodies
Western Blot (WB) and immunohistochemistry (IHC)
analyses were performed using the following antibodies:
beta actin (AB 6276, Abcam, Cambridge UK); TP53
(D0-1) (sc-126, Santa Cruz Biotechnology, CA, USA);
HER2/ErbB2/Neu (C-18) (sc-284, Santa Cruz Biotechnol-
ogy); Keratin 7 Ab-2 (MS-1352-P, NeoMarker, Medicorp,
Qc, Canada); Keratin 8 Ab-4 (MS-997-P, NeoMarker,
Medicorp); Keratin 18 (DC-10) (sc-6259, Santa Cruz Bio-
technology); Keratin 19 Ab-1 (MS198-P, Lab Vision Corp.,
CA, USA), and Keratin 20 (SPM140) (ab15205, Abcam).
Immunohistochemistry
Tissue sections were fixed in formalin and embedded in
paraffin blocks. Sections (4 μm thick) were cut and slides
were stained using the immunoperoxidase method. Tis-
sue sections were heated (37°C overnight or 60°C for
30 minutes), deparaffinized in toluene and rehydrated in
ascending concentrations of ethanol. Slides were then
heated in boiling citrate buffer (0.01 M citric acid, pH
6.0) to unmask antigens. A 0.3% H2O2 treatment was
used to eliminate endogenous peroxidase activity. The
sections were blocked with a protein blocking serum-
free reagent (DakoCytomation, ON, Canada) and incu-
bated with the antibody used for western blotting for
60 min at room temperature. Tissues were incubated
with a secondary biotinylated antibody (DakoCytoma-
tion) for 20 min followed by incubation with a
streptavidin-peroxidase complex (DakoCytomation) for
20 min at room temperature. Staining was visualized
using diaminobenzidine containing a peroxidase sub-
strate (DakoCytomation). Hematoxylin was used as the
counterstain and all sections were observed by light mi-
croscopy and pictures were taken at 40x magnification.
Substitution of the primary antibody with phosphate
buffered saline served as a negative control.Mutation analysis
DNA was extracted from cell lines as described previ-
ously [25]. TP53 mutations were initially detected by
single-strand conformation polymorphism (SSCP) ana-
lysis of exons 5 to 9 of TP53 as described [19]. Band-
shifts were confirmed by Sanger sequencing analysis
(McGill University and Génome Québec Innovation
Centre, Montréal, Québec, Canada). Samples negative
by SSCP analysis were subsequently sequenced by San-
ger sequencing for the coding exons 2–11. Mutation
hotspots in BRAF (exon 11, exon 15) and KRAS (exon
2) were analyzed by either SSCP or sequencing as
described [19]. Sequence chromatograms were com-
pared with NCBI reference sequences reported in Gen-
Bank: NM_000546.4 (TP53), NM_004985.3 (KRAS) and
NM_004333.4 (BRAF). In addition, TP53 variants were
evaluated based on information in the International
Agency for Research on Cancer (IARC) TP53 Database
[27]. As the ovarian cancer specimens were derived
from French Canadian women, a population known to
exhibit founder effects and harbor recurrent BRCA1
and BRCA2 mutations [28], peripheral blood lympho-
cytes from each patient was investigated for the
most common mutations in BRCA1 (4446C >T and
2953delGTAinsC) and BRCA2 (8765delAG, 6085 G >T
and 3398delAAAAG) as previously described [28].Spheroid assay
A spheroid assay was conducted to determine the ability
of cell lines to generate three-dimensional structures in
the form of aggregates, as previously described [20,21].
Briefly, 4 × 103 cells were suspended in 16 μl of
complete OSE medium and placed on the cover of non-
coated plastic tissue culture plates that were subse-
quently inverted. Phosphate buffered saline (1 x PBS)
was added to the bottom plate to prevent dehydration
of droplets. Spheroid formation ability was assessed in
complete OSE medium after four days of incubation at
37°C, 5% O2, 5% CO2, with spheroid formation of the
cell lines being classified concordant with previous re-
search [19,21].Anchorage independent growth in soft agar
Cell lines were assayed for their ability to grow in an-
chorage independent conditions by culturing 2 x 104
cells in a semi-solid media containing noble agar. Cells
were included in the top layer formed of 0.33% w/v agar
in complete OSE medium that was applied over a base
layer (0.66% w/v agar in complete OSE medium) [25].
Cells were cultured in soft agar for three weeks, and
then colonies that formed were photographed and
counted. Two independent experiments were performed
in triplicate.
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Migration potential was evaluated using the scratch
assay method as previously described [3,19,29]. Cells
were grown to confluence in 6-well culture plate dishes.
Using a 200 μl pipette tip, a wound was produced in the
monolayer at different positions. The adherent mono-
layer was washed with 1x PBS to remove non-adherent
cells and complete OSE media was then added. The
same scratch was followed over time and photographed
at different time points (0 h, 8 h, 24 h, 48 h). All experi-
ments were conducted in triplicate and repeated at least
twice.
In vivo growth in SCID mice
The tumorigenic potential of cell lines was assessed
based on their ability to form tumors in 50 day-old fe-
male SCID (severe combined immunodeficiency) mice,
and NOD SCID (Charles River Laboratories, Saint-Con-
stant, QC) at subcutaneous left gluteal injection sites. A
volume of 200 μl was injected in each mouse and con-
sisted of 5 × 106 cells resuspended in 100 μl of cold
phosphate buffered saline (D-PBS) (Gibco™, Invitrogen,
Burlington, ON) and 100 μl of Matrigel (Becton-Dickin-
son, Franklin Lakes, NJ). The animals were housed
under sterile conditions in a laminar flow environment
with ad libitum access to food and water. Tumor forma-
tion was assessed twice a week for over 100 days. Ani-
mals were sacrificed before neoplastic masses reached
limit points established by the Institutional Committee
on Animal Protection (CIPA) according to the Canadian
Council on Animal Care.
Clonogenic assay
Chemotherapy sensitivity of cell lines was assessed using
a clonogenic assay [30]. Briefly, cells were seeded in a 6-
well dish at a number of cells/well that was determined
to allow the formation of individual colonies (TOV1369,
500 cells/well; OV1369(R2), 200 cells/well; OV2295, 1 ×
103 cells/well; OV2295(R2), 2 × 103 cells/well; TOV2295
(R), 2 × 103 cells/well; TOV3133G, 2.5 x 103 cells/well;
TOV3133D, 1 × 103 cells/well; OV3133(R), 1 × 104
cells/well; OV3133(R2), 5 × 104 cells/well). Cells were
seeded and allowed to adhere for 16 hours in a 37°C, 5%
CO2, 5% O2 incubator after which the media was
removed and replaced with OSE complete media con-
taining paclitaxel (0–300 nM), or carboplatin (0–
300 μM) (McKesson Canada, Saint-Laurent, Qc, Ca).
Cells were incubated with the drug for 24 hours. The
drug was then removed, cells were washed with 1 x PBS
and OSE complete media was added. Media was chan-
ged weekly until colonies were visible. Colonies were
then fixed with cold methanol and colored with Giemsa
(Sigma–Aldrich Inc., St. Louis, MO). Colonies were
manually counted and reported as percent of control.IC50 values were determined using Graph Pad Prism 3
software (GraphPad Software Inc., San Diego, CA). Each
individual experiment was performed in triplicate and
repeated three times.
Results
Clinical information, cell line development and tumor
tissue phenotype
Patient 1369 was previously diagnosed with breast can-
cer 18 months prior to her ovarian cancer diagnosis. Fol-
lowing surgical resection for breast cancer, she received
docetaxel treatment, which was completed 14 months
prior to her ovarian cancer diagnosis. She also entered a
clinical trial, NSABP B-30 BRAS1 (doxorubicin, doce-
taxel with or without cyclophosphamide). She also
received radiotherapy 12 months prior to her ovarian
cancer diagnosis. After ovarian cancer diagnosis, she
received a treatment of paclitaxel and carboplatin for
5 months. Based on the serum CA-125 levels (Figure 1),
patient 1369 was initially responsive to the treatment,
but due to carboplatin toxicity she was subsequently
treated with paclitaxel alone. This regimen was discon-
tinued after two cycles as CA-125 levels continued to in-
crease. Patient 1369 had a relapse, based on X-ray
computed tomography (CT), 7 months after cancer diag-
nosis. She then received 11 cycles of doxorubicin (month
8 to month 17). CA-125 levels decreased for the first
few months following the initiation of this regimen but
began to rise 6 months into the treatment (Figure 1).
Topotecan was the final treatment administered from 18
to 28 months.
Patient 2295 was diagnosed with ovarian cancer fol-
lowing imaging, ascites puncture and partial ommentect-
omy. She was then included in a clinical trial, OV-16
BRAS1 (cisplatin/topotecan) for the first four months
following diagnosis during which period her CA-125
levels decreased significantly, from 6000 units/ml to
lower than 50 units/ml during days 96 through 200
(Figure 1B). From month four to seven, she received car-
boplatin and paclitaxel as part of the clinical trial OV-16
BRAS2. She first responded to the chemotherapy with a
clear reduction of the tumor masses. However three
months after the termination of chemotherapy, ascites
volume increased and CA-125 levels increased dramatic-
ally from less than 100 units/ml at day 243 to greater
than 10000 units/ml at day 330 (Figure 1B). Ten months
following diagnosis, the patient underwent ovarian
cytoreduction. Due to a relapse, eleven months after
diagnosis, she received low doses of doxorubicin, to
which she did not respond.
Patient 3133 received a treatment of paclitaxel and carbo-
platin one to three months after surgery and confirmation
of the ovarian cancer diagnosis. CA-125 levels showed a























































































Figure 1 Variation of CA-125 level over the course of the treatment of the three patients A) 1369, B) 2295 and C) 3133. The type and
length of chemotherapy treatment and time at which each cell lines were derived is also indicated. Note that the Y-axis is different for each
patient.
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masses in the abdomen and in lymph nodes. A second sur-
gery was performed almost six months after the first sur-
gery, which showed an infiltration of the tumor in many
areas of the abdomen. It has been concluded that the pa-
tient was resistant to her first treatment of chemotherapy.
Six months after her first diagnosis, she was then put ondoxorubicin for a total of five months. Again, no amelior-
ation of the CA-125 levels was noted, and imaging detected
disease evolution. The patient received carboplatin and
gemcitabine 13 months after her diagnosis, for a total of
6 months. After an initial decrease in CA-125 levels from
1131 units/ml to 680 units/ml, CA-125 levels remained
relatively stable (Figure 1), however imaging showed an
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months after her diagnosis, she received etoposide orally
for eight days.
The cell lines were developed from samples from
patients 1369, 2295 and 3133. All patients had high
grade and late stage (IIIC) cystadenocarcinomas, of the
serous papillary histopathology (Table 1). Patients had
sub-optimal surgical debulking, and all individuals died
from disease progression. The cell lines were derived
from samples collected at diagnosis and at the time of
relapse, from either solid tissue (TOV) or ascites (OV).
In total there were four pre-chemotherapy cell lines
derived from primary disease (TOV1369, OV2295,
TOV3133G and TOV3133D) and five post-chemotherapy
cell lines derived from recurrent (R) disease (OV1369(R2),
OV2295(R2), TOV2295(R), OV3133(R) and OV3133(R2))
(Figure 1). Note that we consider TOV1369 to be a pre-
chemotherapy for ovarian cancer treatment, although the
patient did receive chemotherapy treatment for breast
cancer 18 months prior to ovarian cancer diagnosis.
After 60 passages, the cell lines appeared homoge-
neous and no fibroblast like cells could be detected
(Figure 2, A-I). Although cell shape varied for each cell
line, the morphology was consistent among the lines
derived from the same patient samples.
Figure 2 J to M shows hematoxylin and eosin staining
of sections from the solid tumor tissue corresponding toTable 1 Clinical data of patients 1369, 2295 and 3133 from w
Clinical parameters 1369 2295
Age at diagnosis 58 59
Tumor type adenocarcinoma adenocarcinom
Histopathology sub-type serous papillary serous
Tumor grade G3 G3
Disease stage IIIC IIIC
Ascites at surgery yes yes
Surgical debulking sub-optimal sub-optimal
Progression yes yes
Death yes yes
Cause of death disease progression disease progressi








2 [19] Details pertaining to patients 112 and 1946 are also included, from previouscell line TOV1369, TOV2295(R) and TOV3133G and
TOV3133D.
Expression of keratin markers, TP53 and HER2 in tumor
tissue and cell lines by Western blot and
immunohistochemistry
In order to investigate the epithelial origin of the tumors
and corresponding cell lines, keratin expression was
investigated by both Western blot analysis and immmu-
nohistochemistry. All of the keratins investigated by
Western blot (keratin 7, 8, 18 and 19) were present in
the protein extract of each of the nine cell lines
(Figure 3A). Expression of keratins 7, 8, 18 and 19 was
also observed by immunohistochemistry using sections
of the solid tumor (Figure 4). Keratin 20 expression was
also investigated in ovarian solid tumors (1369, 2295 and
3133) and from two colon cancer tissues, the latter being
used as a positive control for keratin 20. No staining was
observed in ovarian tissue, but positive staining was evi-
dent in the colon tissue (Additional file 1). Expression of
the tumor suppressor p53 was found to be present in
1369 and 2295 derived cell lines, but could not be
detected in the 3133 cell lines TOV3133D, TOV3133G,
OV3133(R) and OV3133(R2) (Figure 3B). Western blot
results for p53 were also confirmed by immunohisto-
chemistry, with p53 showing low expression in the
TOV3133 D and TOV3133G tissues but much higherhom the cell lines were derived
Patients
3133 112 1 1946 2
52 42 75
a adenocarcinoma adenocarcinoma adenocarcinoma













TOV1369 p65 OV1369(R2) p66 OV2295 p67
CBA
OV2295(R2) p67 TOV2295(R) p63 TOV3133D p62
FED





Figure 2 Morphology of cell lines developed from patients 1369, 2295 and 3133 (A-I), including both primary and recurrent cell lines.
Passages were between 61 and 67 for each cell line. By the later passages, cell lines had developed into predominantly small epithelial type cells,
often aggregated. There was a notable absence of fibroblast cells. Hematoxylin and eosin staining is shown in J-M for solid tumor from patients
1369, 2295 and 3133. Images are taken at x40 magnification. Note that the (t) designation denotes that the primary tumor tissue was
investigated.
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Strong HER2 expression was detected in protein extracts
of all nine cell lines (Figure 3B), and was also observed
in the solid tissues by immunohistochemistry (Figure 4).
Mutation status of TP53, BRCA1, BRCA2, KRAS and BRAF
Each of the cell lines harbored a TP53 mutation as veri-
fied by sequence analysis (Table 2). The mutation identi-
fied varied with each patient sample but were identical
in the cell lines derived from the same patient samples.
All variants are considered deleterious based on infor-
mation from the IARC TP53 Database [27]. Although
the mutations are predicted to affect the DNA binding
domain, the cell lines with missense TP53 mutations
tested positive for p53, whereas the cell lines with the
nonsense mutation exhibited no evidence of p53 by
Western blot analysis (Figure 3). The cell lines did not
harbor the most commonly reported KRAS or BRAF
mutations nor the most common BRCA1 and BRCA2
mutations identified in the French Canadian breast and
ovarian cancer families [28].
Cell growth rate and oncogenic assays
The growth rates of the cell lines was determined
(Table 2, Figure 5) and compared with TOV112D andTOV1946, cell lines previously developed by our labora-
tory derived from endometrioid and serous EOC re-
spectively [19]. The proliferation of the cell lines is
depicted in Figure 5. There was no difference in the
doubling time for the three cell lines derived from 2295
(Table 2). OV1369(R2) had a greater proliferation rate
than TOV1369. OV3133(R2) had a slower growth rate
than the other 3133 cell lines (Figure 5). Similarly, the
growth rates, as measured by doubling time, of all nine
cell lines was slower than the pre-chemotherapy highly
aggressive cell line TOV112D [19]. Doubling times ran-
ged from 2.5 to 3.2 days, compared to 1.5 for TOV112D.
There was no consistent difference in doubling between
cell lines derived pre versus post chemotherapy among
the three patients. Saturation densities were typically
lower than what we could observed for TOV112D, being
between 25% to 50% of the value obtained for TOV112D
(Table 2), and more in line with the previously densities
described for other serous ovarian cancer cell lines, such
as TOV1946 and TOV2223 [19].
The cell line’s ability to form spheroids was measured
using the hanging droplet method as previously described
[21]. Although there was some variation among the repli-
cates, none of cell lines consistently formed compact
spheroids, as was clearly observed with TOV112D. Four
AB
Figure 3 Detection of various keratins (KRT) by Western blot
(A) to confirm the epithelial origin of cell lines. B) p53 and
HER2 expression by Western blot. Note the absence of detectable
expression of p53 for the 3133 cell lines. Beta actin was used as a
loading control.
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could form semi-compact spheroids, while OV1369(R2),
TOV2295(R), OV3133(R2), and TOV1946 formed numer-
ous individual small aggregates and TOV1369 and
OV3133(R) would not form spheroids (Table 2, Figure 6).
The migration potential of the cell lines was measured
using an established scratch migration assay. There were
no notable differences in migration rates between the
cell lines. All cell lines migrated slowly and did not fill
the gap within 48 hours, which is slower than what was
observed with TOV1946 [19] (see also Additional file 2).
Using the soft agarose assay, the anchorage depend-
ency of the cells lines was investigated. After three weeks
there were visible colonies formed with the OV1369(R2),
OV2295(R2), TOV2295(R), TOV3133D and OV3133(R2)
cell lines (Table 2).Xenograft tumor formation
The in vivo growth potential of the cell lines was deter-
mined by subcutaneous injection of cells into SCID mice
(n = 6 mice for each group, with the exception of
OV1369(R2) (5), TOV1946 (3) and TOV112D (3)). Only
OV3133(R) formed tumors in SCID mice (66.7% of
mice), whereas all other cell lines failed to induce any
tumor formation (Table 2). The tumorigenic cell lines,
TOV112D and TOV1946, both formed tumors in all
mice. For cell line OV3133(R), the average length of
tumor appearance was 55 days, which is considerably
longer compared to a cell line derived from a more ag-
gressive tumor such as TOV112D, which formed tumor
within less than ten days. Also, the tumor volume
formed with OV3133(R) was smaller than that derived
with TOV112D (Additional file 3) [19]. Specifically, the
average volume was about 350 mm3 for OV3133(R) after
85 days whereas those with TOV112D and TOV1946
reached 3000 mm3 in less than 30 days. All other cell
lines formed masses that remained at 100 mm3 or less
for the length of the experiment (Additional file 3). Note
that on histological examination of the tumors derived
from the OV3133(R) xenograft revealed an undifferenti-
ated tumor of epithelial type cells, characteristic of high-
grade serous tumors. The use of NOD-SCID mice did
not appear to affect the ability of the cell lines to grow
as xenografts (Additional file 4).
In vitro chemosensitivity
The cell lines were investigated for their sensitivity to
carboplatin and paclitaxel by determining a dose re-
sponse curve (Figure 7) obtained from clonogenic assay
data. The IC50 was calculated from these curves to allow
comparison between the cell lines. Data from previously
published cell lines, TOV112D and TOV1946, are
included in Figure 7 for comparison.
For the 1369 cell lines (TOV1369, OV1369(R2)), IC50
values were much higher than other cell lines studied for
carboplatin (5.6 ± 1.3 μM and 8.9 ± 5.0 μM, respectively)
but more comparable to the values obtained with
TOV112D and TOV1946 (Table 2, Figure 7). In the case
of carboplatin, the post-chemotherapy cell line OV1369
(R2) demonstrated a higher IC50 than the pre-
chemotherapy TOV1369, but the difference was not sig-
nificant (t-test p = 0.144). For paclitaxel, the IC50 values
of TOV1369 (22.8 ± 10.7 nM) and OV1369(R2)
(9.13 ± 6.88 nM) suggest a lower sensitivity to the drug
when compared to the other cell lines tested (Table 2).
For 2295, the IC50 calculated for carboplatin for the two
post-chemotherapy cell lines, OV2295(R2) and TOV2295
(R) (0.84 ± 0.24 μM and 0.93± 0.06 μM, respectively) were
more than ten fold higher than the IC50 of the pre-
chemotherapy cell line OV2295 (0.05 ± 0.01 μM)(1-way
























Figure 4 Immunohistochemical analysis of paraffin embedded solid tumors (TOV1369, TOV2295(R), TOV3133D and TOV3133G) with
keratin markers, p53 and HER20. Nuclei are counterstained with hematoxylin, and images are at x400 magnification. Positive staining was seen
for all solid tumors for each keratin tested, and HER2. Note the lower expression detected for p53 in TOV3133D and TOV3133G. Note that the (t)
designation denotes that the primary tumor tissue was investigated.
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determined IC50 for OV2295, OV2295(R2) and TOV2295
(R) were 5.43± 4.73, 1.99± 1.48 and 1.87± 0.31 nM,
respectively. These results suggest that patient 2295
acquired resistance to carboplatin, but not to paclitaxel.
For the pre- and post-chemotherapy cell lines derived
from patient 3133, there was no notable difference in che-
mosensitivity for either carboplatin or paclitaxel (Figure 7,
Table 2). The IC50 for the 3133 cell lines ranged between
0.75±0.63 μM (TOV3133G) to 2.65 μM (OV3133(R2)) for
carboplatin, and from 1.59 nM (OV3133(R2)) to 5.54±3.19
nM (OV3133(R)) for paclitaxel. Note that the IC50 value for
OV3133(R2) was based on one experiment conducted in
triplicate due to the low clonogenic efficiency of OV3133
(R2). There was no difference in IC50 values between the
pre- and post-chemotherapy cell lines derived from patient
3133 for either carboplatin or paclitaxel.
Discussion
We report here on matched EOC serous cell lines
derived from solid tumor or ascites samples from thesame patient at time of diagnosis and following recur-
rence. Ovarian epithelial cells typically express keratin 7
but lack expression of keratin 20 [31-33]. This pattern
was observed in the tumor tissues of all patients by both
Western blot and immunohistochemistry (Figure 3;
Figure 4 and Additional file 1. Taken together, we were
able to confirm the epithelial origin of the cell lines pre-
sented here.
The cell lines were characterized in terms of TP53
mutation status and protein expression, BRCA1, BRCA2,
KRAS and BRAF mutation status, and HER2 expression.
All of the cell lines had a somatic TP53 mutation, which
is consistent with the reported frequency in high-grade
serous tumors, estimated at 51 to 93% in recent studies
[34-37]. An identical mutation was evident in each cell
line derived from the same patient, consistent with a
common clonal origin for the tumor and ascites derived
from each individual patient. As expected, identical
TP53 mutations to those found in the cell lines were
also observed in the corresponding tumor tissue (data
not shown). The expression of TP53 was investigated in
Table 2 Cell growth characteristics, IC50 values and mutation status of ovarian cancer cell lines derived either at initial diagnosis (TOV1369, OV2295,
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5.64 ± 1.29 8.91 ± 5.00 0.05 ± 0.01 0.84 ± 0.25 0.93 ± 0.06 0.75 ± 0.63 1.75 ± 0.88 1.34 ± 0.37 2.65 13.96 4.04 ± 4.19
Paclitaxel (nM)
(avg ± SD)
22.8 ± 10.7 9.1 ± 6.9 5.4 ± 4.7 2.0 ± 1.5 1.9 ± 0.3 3.5 ± 0.9 2.8 ± 0.3 5.5 ± 3.2 1.6 1.9 3.5 ± 1.8
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1Calculated from two independent experiments (in triplicate);
2Time to tumor appearance is based on the average of the 4 mice for OV3133(R) that developed tumors, with the tumor mass being greater than 200 mm3;
3Calculated from three independent experiment except for TOV112D and OV3133(R2), which represent triplicate of a single experiment;
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Figure 5 Proliferation of cell lines over 14 days. 1X105 (1369
and 2295 cell lines) or 2X105 (3133 cell lines) cells were seeded
in 6-well plates and trypsinized and counted every 48 hours,
for 13 days. Experiments were performed in duplicate, and
repeated three times. Cell lines derived pre-chemotherapy are
represented by an open symbol, cell lines derived post-







Figure 6 Spheroid formation of cell lines after 4 days in OSE
media using the inverted droplet technique. Spheroid formation
capability ranged from no ability (TOV1369 and OV3133(R)) to a
compact spheroid (TOV112D). Photos are representative of
observation from two independent experiments.
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http://www.biomedcentral.com/1471-2407/12/379all of the cell lines by Western blot and in the primary
solid tumors by immunohistochemistry. Interestingly,
p53 was not detected by Western blot in all four 3133
cell lines (and confirmed by a low expression by immu-
nohistochemistry). This is consistent with the truncating
nonsense mutation in exon 6 in the TP53 sequence
found in each of the 3133 cell lines. Expression of the
epidermal growth factor receptor gene, HER2, which is
implicated in malignant transformation, was also used to
characterize the cell lines, as overexpression is reported
on average in 20-30% of ovarian tumors and as high as
75% by a variety of techniques including ELISA, immu-
nohistochemistry and RT-PCR [38-41]. Although there
is evidence of overexpression of HER2 being associated
with a lower sensitivity to platinum-based chemotherapy
Figure 7 Chemosensitivity of ovarian cancer cell lines to carboplatin and paclitaxel determined by clonogenic assay. Log10 data of drug
concentrations is presented versus the percentage of control. Doses ranged from 0–300 μM for carboplatin, and from 0–300 nM for paclitaxel.
The graphs represent the average +/− SD of three independent experiments. For TOV112D, it is average +/− SD of a single experiment
conducted in triplicate. There was a significant difference between the IC50 value of carboplatin for OV2295, and OV2295(R2) and TOV2295(R)
(1-way ANOVA, p < 0.001).
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http://www.biomedcentral.com/1471-2407/12/379[41], there was no indication of differential expression in
the ovarian cancer cell lines by Western blot, or in the
solid tumors by immunohistochemistry that could relate
to the sensitivity to carboplatin detected by the clono-
genic assay.
The distinct tumor growth characteristics within the
serous cell lines derived here, indicates a diversity re-
flective of the heterogeneous nature of this histopatho-
logical subtype. For example, saturation density,
spheroid formation and colony formation in soft agarose
differed between cell lines, and also within cell lines
derived from the same patient. Differences in spheroid
formation between cell lines derived before and after
chemotherapy treatment may offer an interesting point
of reference, especially as spheroid models may offer a
model system more in line with the in vivo tumor setting
[21]. For example, the cell line OV2295 formed semi-
compact spheroids, compared to the aggregates in
TOV2295(R), possibly reflecting differences in cell to cell
adhesion. When comparing cell lines derived from a sin-
gle patient over time, there is no tendency to be more
aggressive in terms of the measured characteristics as
the disease progresses. Nevertheless, the current model
will allow researchers to address biological questions in-
trinsic to the cell lines such as clonal heterogeneity
within tumors, as well as modification occurring for the
development of ascites [42] and the relationship between
biological properties of ascites and solid tumors estab-
lished from the same patient [19]. In addition, the fur-
ther investigation of genetic and epigenetic changes
between the primary tumor and cell lines at discrete
time points may provide insight into the evolutionary
processes at play in cancer development [43].
Interestingly, in vivo tumor formation of the cell lines
in SCID mice at subcutaneous sites was only observed
with OV3133(R), the first ascites taken from patient
3133. The second ascites sample OV3133(R2) that was
taken after doxorubicin treatment, at approximately
500 days after the OV3133(R) was sampled, did not form
tumors. The tumors formed in SCID mice grew slowly
as compared with the previously established TOV112D
and TOV2295(R) cell lines, although this observation
was consistent with previously studied high grade serous
cell lines such as TOV2223 which also did not form
tumors at subcutaneous sites in SCID mice [19]. Al-
though the cell lines outlined here may not be amenable
to all pre-clinical xenograft models, in the future we
may be able to investigate intraperitoneal injections.
Note also that the lack of tumorigenicity in mouse xeno-
graft model may not reflect the situation in humans –
this should not be used as the sole criteria for cell line
utility.
The new cell lines derived in this study were devel-
oped from patient samples that were exposed to specificchemotherapeutic agents. This is in contrast to che-
moresistant cell lines generated in vitro, which are often
derived from clonal variants that survive by escalating
dosages of chemotherapeutics. In contrast, the cell lines
we describe here may more accurately represent the mo-
lecular evolution that occurs within the tumor micro-
environment. Additionally, we have already alluded to
the potential to further study the cell lines by utilizing
the spheroid model, which may more accurately reflect
the in vivo tumor environment [21]. For example, L’Es-
perance et al., 2008 used the spheroid model of ovarian
cancer cell lines (OV90, TOV21G, TOV112D) to investi-
gate response to chemotherapy treatment [44]. Interest-
ingly, higher levels of both cisplatin and paclitaxel were
required for a similar response in spheroids compared to
a similar study using monolayers on the same cell lines
[45]. This suggestion of greater drug resistance in spher-
oids warrants further attention in the present set of cell
lines.
Of the patients from which the cell lines were estab-
lished, two of the three (1369 and 2295) responded ini-
tially to first line therapy using Response Evaluation
Criteria in Solid Tumors (RECIST) criteria [46,47]. In
general, response rates for chemotherapy in ovarian can-
cer are reported at 70-80% [48]. Patient 3133 did not
show a clear response to chemotherapy, with evidence
of progressive disease after 5 months by RECIST criteria.
However, CA-125 levels showed a marked decrease from
764 before the initial paclitaxel/carboplatin treatment to
470 units per ml two months following treatment . This
decrease of nearly 40% is just outside the level of de-
crease which would be indicative of a responder, based
on the GCIG (Gynecological Cancer InterGroup) accept-
able current criteria for CA-125 response, of at least a
50% decrease in CA-125, for at least 28 days[46,47]. Al-
though no significant differences were observed in re-
sponse to paclitaxel in the cell lines derived from
primary versus recurrent disease, previous studies have
indicated otherwise, such as described in a recent report
which determined that 35% of solid tumors and 50% of
ascites samples were resistant to paclitaxel [49]. It is
noteworthy that the IC50 levels of paclitaxel response in
TOV1369 and OV1369(R2) are four-to-twenty and two-
to-five times higher, respectively, than all other cell lines
examined, and this is possibly due to acquired resistance
to taxol as a consequence of prior treatment for breast
cancer. We also note that cells from patient 1369 also
displayed a lower sensitivity to carboplatin, although the
clinical profile of this patient does not suggest inherent
chemoresistance. Comparison of the OV2295 (derived
prior to recurrence) to the OV2295(R2) and TOV2295
(R) cell lines derived following recurrence were the only
clear example of acquired resistance to carboplatin. Car-
boplatin resistance is well documented in ovarian cancer.
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and 59% of ascites samples to be resistant to carboplatin
[49]. This is likely due to the selective pressure of the
chemotherapy regime exerted on a heterogeneous cell
population, resulting in an enrichment of a resistant
subset of cells by promoting the expression of a resist-
ance pathway or selection for a population bearing a
mutation responsible for a decrease in sensitivity.
Mutation status such as TP53, BRCA1 and BRCA2
[50,51] are also important factors, which may contribute
to tumor progression and chemoresistance of an ovarian
tumor tissue or cell line, especially in relation to their
role in apoptosis. In this report, based on the investiga-
tion of common French Canadian mutations, no BRCA1
or BRCA2 mutations were identified, and therefore we
cannot comment on the role of BRCA1/2 as a surrogate
marker for chemotherapy response. There did not ap-
pear to be a difference in the specific type of TP53 mu-
tation (truncating nonsense for 3133, missense for 1369
and 2295), relative to chemosensitivity status. Although
there is evidence of overexpression of HER2 being asso-
ciated with a lower sensitivity to platinum-based chemo-
therapy, our results did not show differential expression
in the ovarian cancer cell lines by Western blot, or in
the solid tumors by immunohistochemistry that could
relate to the sensitivity to carboplatin detected by the
clonogenic assay. Therefore we can suggest that BRCA
and HER2 are not linked to the resistance profile pre-
sented in our cell lines and that other factors might be
involved. In the case of p53, there was a difference in
mutant p53 protein expression between TOV1369 and
OV1369(R2), but no corresponding difference in chemo-
therapy response. Although the OV2295 cell line
appeared to have a lower expression of the mutant p53
protein then the recurrent OV2295(R2) and TOV2295
(R) cell lines, both of which exhibited acquired carbopla-
tin resistance, any relationship between mutant p53 ex-
pression and carboplatin resistance would have to be
robustly tested using a gene knock-down experiment.
Furthermore, a study using paired pre- and post-
chemotherapy tumor samples, determined that differ-
ences in gene expression profiles between matched sam-
ples could be due to factors not only involved in
chemotherapy resistance, but also factors related to
tumor progression and proliferation [44,52]. The cell
lines described here may serve as a good model to begin
to analyze specific candidates identified in these studies.
Conclusion
The new ovarian cancer cell lines characterized in this
report provide an important biological resource for
studying the molecular genetic evolution of ovarian can-
cer that reflect the development of disease in the context
of initial diagnosis and following disease recurrence. Thecell lines provide a framework for comparative molecu-
lar genetic studies investigating the genomic landscape
by gene expression, copy number variation or mutation
analysis. The unique phenotypes exhibited by the cell
lines suggest that they reflect the complexity of ovarian
cancer disease. The paired sample cell line model from
patient 2295, will allow for further discrimination of
acquired resistance, affected by the chemotherapy re-
gime. Although cell lines from patient 1369 and 3133 do
not show signs of acquired resistance, both offer avenues
of research into tumor evolution. Specifically, further
study of the1369 cell lines would allow for the under-
standing of the molecular basis for the high innate re-
sistance to both carboplatin and paclitaxel. In 3133,
three distinct time points are represented offering pos-
sible insights into the mechanisms of tumor progression
and evolution.
Additional files
Additional file 1: Keratin 7 and keratin 20 immunohistochemistry in
ovarian tumors from which the cell lines were derived. Paraffin
embedded colon tumors were used as the negative control for keratin 7,
and positive control for keratin 20. Sections were counterstained with
hematoxylin and are shown at x40 magnification.
Additional file 2: Images from the migration assay, indicating
migration of cells during a 48-hours period. Note the closure of the
wound for the TOV1946 cell line after 48 hours.
Additional file 3: Tumor growth in SCID mice following injection of
specific ovarian cancer cell lines. For each cell line, six SCID mice
received subcutaneous injection (5 x 106 cells mixed with Matrigel) (with
the exception of five mice for OV1369(R2), and three mice for TOV112D
and TOV1946). Graphs represent average ± SD of tumor volume as a
function of days following cell injection. Tumor masses were measured at
least twice a week (width x length x thickness). Note that the axis for
TOV112D and TOV1946 is not of the same scale. Cell lines derived pre-
chemotherapy are represented by a closed symbol, cell lines derived
post-chemotherapy have an open symbol.
Additional file 4: Tumor growth in SCID-NOD mice following
injection of specific ovarian cancer cell lines. For each cell line, two
NOD-SCID mice received subcutaneous injection (5 x 106 cells mixed
with Matrigel). Graphs represent average of tumor volume as a function
of days following cell injection. Tumor masses were measured at least
twice a week (width x length x thickness). Note that the axis for TOV112D
and TOV1946 is not of the same scale. Cell lines derived pre-
chemotherapy are represented by a closed symbol, cell lines derived
post-chemotherapy have an open symbol.
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